{'fraction_non_alphanumeric': 0.02977667493796526, 'fraction_numerical': 0.022332506203473945, 'mean_word_length': 4.353982300884955, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Influenza B virus model of Reye's syndrome in mice: The effect of aspirin

Aspirin is a possible cofactor with influenza B virus in Reye's syndrome. In an attempt to determine whether single or multiple doses of acetylsalicylic acid (ASA) alter mortality in an influenza B virus mouse model of Reye's syndrome, either ASA (300 to 667 mg/kg) or saline was given intraperitoneally to 3‐week‐old Balb/c mice. Two hours later, one median lethal dose (LD50) of influenza B/Lee virus was given intravenously. Mortality was not significantly increased by the single ASA dose. Blood ASA levels rose as high as 68 mg/dl. The average ASA blood levels in mice 12 hours after receiving the virus plus 667 mg/kg ASA was 22.6 mg/dl, which was significantly higher than the 3.4 mg/dl for mice who received saline plus ASA. No significant increase in mortality occurred in mice given 67 mg/kg ASA twice daily for 7 days and one LD50 dose of virus on day 4. We conclude that a single dose of ASA at up to half the median lethal dose or multiple doses of ASA do not significantly increase mortality in this influenza virus model of Reye's syndrome. However, influenza B virus infection appears to interfere with ASA metabolism.